NEXT: Lara Bloom, CEO of The Ehlers Danlos Society, Discusses the Future of Rare Disease

November 25, 2019

Lara Bloom, CEO of The Ehlers Danlos Society, discusses the future of rare disease and the challenges that will need to be addressed in this brief interview. It was filmed during the Global Genes’ 2019 Rare Patient Advocacy Summit in September 2019. It coincided with the release of Global Genes’ report NEXT: Imagining the Future of Rare Disease.

Stay Connected

Facebook Twitter Instagram Youtube

NEXT: Lara Bloom, CEO of The Ehlers Danlos Society, Discusses the Future of Rare Disease

Related

Korro Bio Raises $70 Million to Advance RNA Edited Therapies

RNA-Targeted Therapy Shows Promise for a Rare Childhood Dementia

Expanding Access to Genome Sequencing in Rural Populations

A Small Molecule Therapy to Regenerate Muscle in People with DMD

Argenx Highlights gMG Drug Data in CIDP

Group Calls for Use of Genome Sequencing as First Line Test for Patients Suspected of Genetic Disease

FDA Grants Fast Track Designation for Lexeo’s Gene Therapy for Friedreich’s Ataxia Cardiomyopathy

Across Healthcare Enters Collaboration with n-Lorem Foundation to Develop Submission Platform for Docs

A 37-Year Path to a Diagnose, but Now a Drug May Be Two Weeks Away

Stay Connected